Congenital Fibrinogen Deficiency Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Congenital Fibrinogen Deficiency Market Overview
The Congenital Fibrinogen Deficiency (CFD) market size across the three major markets (3MM: the US, Germany, and Japan) was $673.33 million in 2021 and is expected to achieve a CAGR of more than 1% during 2021-2031. The anticipated launch of Biotest/Grifols’ BT-524 is anticipated to propel growth of the market in the coming years. BT-524 is expected to launch in 2024 in Germany, 2025 in the US, and 2027 in Japan.
The CFD market research report provides an analysis of the key dynamics of the CFD drugs market. The report also offers insights into the key industry drivers and challenges. It also covers deals and R&D strategies in detail to highlight potential business opportunities.
The 3MM CFD Market Overview
To gain more information on the CFD market forecast, download a free report sample
CFD Market Drivers
The launch of two improved HFC products during the forecast period (BT-524 and FIB Grifols) will drive an increase in the overall market size of CFD across the 3MM. In addition, the steady increase in population will lead to a higher number of prevalent cases of CFD, resulting in higher rates of diagnosis, treatment, and increased awareness.
CFD Market Unmet Needs and Opportunities
CFD is an extremely rare disease with a small drug-treated patient population; this may discourage companies from investing in the space due to low sales potential. However, there is a need for new and differentiated therapeutic options, improved clinical trial designs, increased physician awareness of CFD symptomatology, and improved patient access and reimbursement for treatment.
Pharmaceutical companies have a large opportunity to develop safer drug options not manufactured from human plasma, and potentially curative gene therapies that target the underlying cause of CFD. Gene therapy holds the potential to dramatically change the way CFD is treated, based on the ability to correct the genetic mutation, and ideally eliminate the need for frequent IV infusions with HFCs.
CFD Market Segmentation by Approved Products
The key approved products in the CFD market are RiaSTAP, Fibryga, FibCLOT, and Fibrinogen HT. During the 2021 base year, RiaSTAP owned the largest market share.
CFD Market Analysis, by Approved Products
For more insights on approved products in the CFD market, download a free report sample
CFD Market - Competitive Landscape
Some of the leading players in the CFD market are Biotest and Grifols. Both of them are working on blood derivative therapeutic classes of drugs.
CFD Market Report Overview
Market Size (2021 in 3MM) | $673.33 million |
CAGR (2021 – 2031) | >1% |
Key Approved Products | RiaSTAP, Fibryga, FibCLOT, and Fibrinogen HT |
Leading Players | Biotest and Grifols |
Scope
This report provides
- Overview of CFD its pathogenicity, manifestations, and types of infection.
- Epidemiology looks into the diagnosed incident and prevalent cases of CFD by sex and by 3MM.
- Overview of diagnostics and treatment, treatment profiles of combination therapy for different CFD strains.
- Quotes from three key opinion leaders (KOLs) from the 3MM.
- Key topics covered for CFD drugs in the 3MM include trends, pipeline and market analysis, opportunities, challenges, and unmet needs.
- Pipeline assessment: emerging novel trends under development, and analysis of the most promising late-stage CFD pipeline drugs in clinical development.
- Analysis of the key dynamics of the CFD drugs market. Insightful review of the key industry drivers and challenges.
- Deals and R&D strategies are covered in detail to highlight potential business opportunities.
Reasons to Buy
The report will help to understand:
- What impact will late-stage pipeline agents have on the market? Which class of CFD drugs will have the highest peak sales, and why?
- What country in the 3MM will experience the most growth, and why?
- What are the current unmet needs and which pipeline drug or strategies are positioned to counter these unmet needs? What are the opportunities for R&D in the CFD space?
- How is the field of CFD therapies going to move forward?
- What is the current and future outlook for CFD therapeutics according to KOLs?
Octapharma
LFB Group
Japan Blood Products Organization
Biotest
Grifols
Table of Contents
Frequently asked questions
-
What was the CFD market size in the 3MM in 2021?
The CFD market was valued at $673.33 million in 2021 in the 3MM (the US, Germany, and Japan).
-
What is the CFD market growth rate?
The CFD market is expected to achieve a CAGR of more than 1% during 2021-2031.
-
What are the key approved products in the CFD market?
The key approved products in the CFD market are RiaSTAP, Fibryga, FibCLOT, and Fibrinogen HT.
-
Who are the leading players in the CFD market?
Some of the leading players in the CFD market are Biotest and Grifols.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.